Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment


Cite item

Full Text

About the authors

Aleksandra Stefaniak

Dermatology, Venearology and Allergology, Wrocław Medical University

Email: info@benthamscience.net

Jacek Szepietowski

Dermatology, Venearology and Allergology, Wrocław Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Pereira MP, Ständer S. How to define chronic prurigo? Exp Dermatol 2019; 28(12): 1455-60. doi: 10.1111/exd.13972 PMID: 31102542
  2. Ständer S, Pereira MP, Berger T, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 2020; 5(4): e42-2. doi: 10.1097/itx.0000000000000042
  3. Labib A, Ju T, Vander Does A, Yosipovitch G. Immunotargets and therapy for prurigo nodularis. ImmunoTargets Ther 2022; 11: 11-21. doi: 10.2147/ITT.S316602 PMID: 35502157
  4. Campion M, Smith L, Gatault S, Métais C, Buddenkotte J, Steinhoff M. Interleukin‐4 and interleukin‐13 evoke scratching behaviour in mice. Exp Dermatol 2019; 28(12): 1501-4. doi: 10.1111/exd.14034 PMID: 31505056
  5. Müller S, Zeidler C, Ständer S. Chronic prurigo including prurigo nodularis: New insights and treatments. Am J Clin Dermatol 2024; 25(1): 15-33. doi: 10.1007/s40257-023-00818-z PMID: 37717255
  6. Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 2017; 171(1): 217-228.e13. doi: 10.1016/j.cell.2017.08.006 PMID: 28890086
  7. Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29(5): 1180-90. doi: 10.1038/s41591-023-02320-9 PMID: 37142763
  8. Gao Z, Dou Y, Zhao P, Wang CJ, Zhang J. Successful treatment of prurigo nodularis by dupilumab: Report of 24 patients. Dermatology 2023; 239(4): 658-63. doi: 10.1159/000529965 PMID: 37011607
  9. Fang HY, Lian CH. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real‐life observational study. J Dermatol 2023; 50(8): 1084-7. doi: 10.1111/1346-8138.16803 PMID: 37088954
  10. Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: A systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat 2022; 33(3): 1547-53. doi: 10.1080/09546634.2020.1853024 PMID: 33200955
  11. Zhang Z, Li S, Wang Y, Zhao J. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis. An Bras Dermatol 2023; 98(4): 440-8. doi: 10.1016/j.abd.2022.09.008 PMID: 36966024
  12. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 2020; 382(8): 706-16. doi: 10.1056/NEJMoa1908316 PMID: 32074418
  13. Ständer S, Yosipovitch G, Lacour JP, et al. Nemolizumab efficacy in prurigo nodularis: Onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol 2022; 36(10): 1820-5. doi: 10.1111/jdv.18377 PMID: 35766128
  14. Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389(17): 1579-89. doi: 10.1056/NEJMoa2301333 PMID: 37888917
  15. Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: A randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine 2023; 57: 101826. doi: 10.1016/j.eclinm.2023.101826 PMID: 36816342
  16. Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D. Benralizumab for chronic spontaneous urticaria. N Engl J Med 2020; 383(14): 1389-91. doi: 10.1056/NEJMc2016395 PMID: 32997916

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers